Navigation Links
First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008
Date:3/24/2009

PARIS, March 24 /PRNewswire-FirstCall/ -- The AXA Research Fund closed out its first year of existence. During the year ended, the Fund granted more than Euro 13 million to various European research institutions.

The purpose of the Fund is to promote the understanding and prevention of major risks in the world by supporting cutting edge scientific research. The AXA Research Fund has been endowed with Euro 100 million over five years, making it a major initiative in the realm of scientific philanthropy in Europe.

"The current environment only reinforces our conviction that academic research is critical to meeting the challenges of a global society," noted Henri de Castries, Chairman of the AXA Group Management Board. "We are particularly proud of the work accomplished by the Fund over the course of this first year, and we confirm AXA's long-term commitment to contributing to emergence of the talents and technologies needed to ensure the development of our societies. Researching today is protecting tomorrow."

In 2008, the AXA Research Fund granted funding to:

Three leading academic institutions:

  • IHES (Institut des Hautes Etudes Scientifiques): Euro 3 million capital endowment for the creation of a permanent Mathematics chair
  • Toulouse Sciences Economiques: Euro 3 million capital endowment to the Jean-Jacques Laffont Foundation
  • INSERM - Paris V: Euro 1.25 million financing for the creation of a five-year chair devoted to Longevity Studies

Four multi-year projects conducted by world-class scientific teams:

  • Project on the impact of climate change on major flooding in Europe (Institute for Meteorology in Berlin)
  • Project dedicated to the study of the impact and dynamics of marine aliens in the context of climate change (Queen's University Belfast)
  • Project dedicated to assessing civil conflict risks (Universitat Autonoma of Barcelona)
  • Project entitled A structural approach to inflation and term structure (EDHEC Business School of Lille)

58 young researchers of promise, working in 13 countries

  • 28 postdoctoral fellowships of Euro 60,000 each
  • 30 doctoral fellowships of Euro 120,000 each

"The AXA Research Fund chose to help outstanding institutions widen their reach in a sustainable manner, through capital endowments, a tool that is very new to Western Europe," said Ezra Suleiman, president of the Scientific Board. "We wanted to guarantee absolute independence and freedom to the researchers who receive our funding, since they are critical to success. We plan to pursue our action in 2009, and will bolster the international dimension of our investments."

Information about the AXA Research Fund, in particular that pertaining to the selection criteria and process for researchers and institutions interested in being considered for financial assistance can be found at our website: http://researchfund.axa.com

About AXA

AXA Group is a worldwide leader in Financial Protection. AXA's operations are diverse geographically, with major operations in Europe, North America and the Asia/Pacific area. For full year 2008, IFRS revenues amounted to Euro 91.2 billion and IFRS adjusted earnings to Euro 3.7 billion. AXA had Euro 981 billion in assets under management as of December 31, 2008.

The AXA ordinary share is listed on compartment A of Euronext Paris under the ticker symbol CS (ISIN FR0000120628 - Bloomberg: CS FP - Reuters: AXAF.PA). The American Depository Share is also listed on the NYSE under the ticker symbol AXA.

This press release is available on the AXA Group website: www.axa.com

    AXA Media Relations:
    Emmanuel Touzeau:      +33.1.40.75.46.74
    Laurent Secheret:      +33.1.40.75.48.17
    Armelle Vercken:       +33.1.40.75.46.42

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements contained herein are forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties. Please refer to AXA's Annual Report on Form 20-F and AXA's Document de Reference for the year ended December 31, 2007, for a description of certain important factors, risks and uncertainties that may affect AXA's business. In particular, please refer to the section "Special Note Regarding Forward-Looking Statements" in AXA's Annual Report on Form 20-F. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise.


'/>"/>
SOURCE AXA Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
2. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
3. First Swiss Patients Treated with the Percutaneous MitraClip(R) System
4. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
5. A First-Line Therapy for Renal Cell Carcinoma that can Increase Overall Survival when Compared with Sutent Would Earn a Higher Patient Share in the United States Than in Europe
6. IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
7. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
8. Positive Data From Lung Study May Lead to First FDA Approved Treatment for Pulmonary Fibrosis
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. First U.S. Patients Enrolled in the REALISM Continued Access Study
11. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... -- Summary Breast cancer, a malignant neoplasm, is ... cancer in women worldwide, accounting for 16% of all ... of women diagnosed with breast cancer has increased over ... has declined due to earlier diagnosis and better treatment ... the past four decades, especially with increasing usage of ...
(Date:2/4/2016)... MOUNTAIN VIEW, Calif., Feb. 4, 2016  Omnicell, Inc. (NASDAQ: ... supply management solutions to healthcare systems, today announced results ... 2015.  --> --> ... was $130.3 million, up $5.1 million or 4.1% from ... or 7.2% from the fourth quarter of 2014. Revenue ...
(Date:2/4/2016)... , Feb. 4, 2016 In response to the ... FDA,s Deputy Commissioner for Medical Products and Tobacco, along with ... reassess the agency,s approach to opioid medications. The plan will ... providing patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at ... of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and ... , For Valentine’s Day, not only are long-stem roses available, but also other flower ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... ... February 05, 2016 , ... The ... funding innovative lymphoma research and serving the lymphoma community through a comprehensive series ... again host, Swirl, A Wine Tasting Event at the La Gorce Country Club ...
(Date:2/5/2016)... Dallas, Texas (PRWEB) , ... February 05, 2016 , ... ... to allow users to search for and donate to Give To Cure’s campaign ... is an app that lets users make and share payments through a smart device. ...
(Date:2/5/2016)... MA (PRWEB) , ... February 05, 2016 , ... ... in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal today, ... option with unmatched results. , Developed by Cynosure, the PicoSure has been approved by ...
Breaking Medicine News(10 mins):